Christopher G. Hayes

This profile gathers the share dealings of Christopher G. Hayes in Verrica Pharmaceuticals Inc., where the filings describe the role as senior executive. Between 4 June 2021 and 17 March 2025, the trades on record add up to 15 filings.

The open-market side counts 3 purchases for €57k alongside 8 sales for €467k. On balance, insiders were net sellers of €409k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 4 share grants. Since January 2025: no purchases and 1 sale on the market.

In size, the median ticket on the buying side is €20k. Clusters matter here: 3 out of 3 purchases overlapped with buying by a colleague within 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.

The latest filing, published on 18 March 2025, reports an open-market sale of €2,578 in Verrica Pharmaceuticals Inc. The latest purchase dates back some time: it was published 1,566 days ago, on 11 July 2022. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.